Inhibitory effect of paclitaxel and rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade

Molecular Pharmaceutics

Volumn 10, Issue 5, 2013, Pages 2071-2078

  Mishra, Gyan P ^a   Nguyen, Duc ^a   Alani, Adam W G ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

antiangiogenesis; combination therapy; polymeric micelles

Indexed keywords

CASPASE 3; CASPASE 7; DIMETHYL SULFOXIDE; MACROGOL DERIVATIVE; PACLITAXEL; POLY(ETHYLENE GLYCOL) BLOCK POLY(LACTIC ACID); POLYMER; RAPAMYCIN; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; DRUG CARRIER; MICELLE; MONOMETHOXYPOLYETHYLENEGLYCOL-POLYLACTIDE BLOCK COPOLYMER;

ANGIOGENESIS; APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG INHIBITION; DRUG POTENTIATION; DRUG SOLUBILITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MEDIATOR; MICELLE; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN INDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; CELL MOTION; CHEMISTRY; DRUG EFFECTS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PATHOPHYSIOLOGY;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICELLES; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SIROLIMUS;

EID: 84877245753     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400122m     Document Type: Article

References (44)

1. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 1990, 82, 4-6
2. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch Nat. Rev. Cancer 2003, 3, 401-410
3. Kuwabara, K.; Ogawa, S.; Matsumoto, M.; Koga, S.; Clauss, M.; Pinsky, D. J.; Lyn, P.; Leavy, J.; Witte, L.; Joseph-Silverstein, J. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 4606-4610
4. Eichhorn, M. E.; Kleespies, A.; Angele, M. K.; Jauch, K. W.; Bruns, C. J. Angiogenesis in cancer: molecular mechanisms, clinical impact Langenbecks Arch. Chir. 2007, 392, 371-379
5. Rosen, L. Antiangiogenic strategies and agents in clinical trials Oncologist 2000, 5, 20-27
6. Papetti, M.; Herman, I. M. Mechanisms of normal and tumor-derived angiogenesis Am. J. Physiol. Cell Physiol. 2002, 282, C947-C970
7. Bocci, G.; Francia, G.; Man, S.; Lawler, J.; Kerbel, R. S. Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy Proc. Natl Acad. Sci. U.S.A. 2003, 100, 12917-12922
8. Bocci, G.; Nicolaou, K. C.; Kerbel, R. S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs Cancer Res. 2002, 62, 6938-6943
9. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C. J.; Zuelke, C.; Farkas, S.; Anthuber, M.; Jauch, K. W.; Geissler, E. K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat. Med. 2002, 8, 128-135
10. Miller, K. D.; Sweeney, C. J.; Sledge, G. W. Redefining the target: chemotherapeutics as antiangiogenics J. Clin. Oncol. 2001, 19, 1195-1206
11. Ng, S. S.; Figg, W. D.; Sparreboom, A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins Cancer Res. 2004, 64, 821-824
12. Belotti, D.; Vergani, V.; Drudis, T.; Borsotti, P.; Pitelli, M. R.; Viale, G.; Giavazzi, R.; Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin. Cancer Res. 1996, 2, 1843-1849
13. Vezina, C.; Kudelski, A.; Sehgal, S. N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle J. Antibiot. 1975, 28, 721-726
14. Gao, H.; Zhang, J.; Liu, T.; Shi, W. Rapamycin prevents endothelial cell migration by inhibiting the endothelial-to-mesenchymal transition and matrix metalloproteinase-2 and -9: an in vitro study Mol. Vis. 2011, 17, 3406-3414
15. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer Cancer Cell 2007, 12, 9-22
16. Yap, T. A.; Garrett, M. D.; Walton, M. I.; Raynaud, F.; de Bono, J. S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises Curr. Opin. Pharmacol. 2008, 8, 393-412
17. Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents Nat. Rev. Drug Discovery 2006, 5, 671-688
18. Torchilin, V. P. Structure and design of polymeric surfactant-based drug delivery systems J. Controlled Release 2001, 73, 137-172
19. Torchilin, V. P. Micellar nanocarriers: pharmaceutical perspectives Pharm. Res. 2007, 24, 1-16
20. Gaucher, G.; Dufresne, M. H.; Sant, V. P.; Kang, N.; Maysinger, D.; Leroux, J. C. Block copolymer micelles: preparation, characterization and application in drug delivery J. Controlled Release 2005, 109, 169-188
21. ten Tije, A. J.; Verweij, J.; Loos, W. J.; Sparreboom, A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy Clin. Pharmacokinet. 2003, 42, 665-685
22. Weiss, R. B.; Donehower, R. C.; Wiernik, P. H.; Ohnuma, T.; Gralla, R. J.; Trump, D. L.; Baker, J. R., Jr.; Van Echo, D. A.; Von Hoff, D. D.; Leyland-Jones, B. Hypersensitivity reactions from taxol J. Clin. Oncol. 1990, 8, 1263-1268
23. Shin, H. C.; Alani, A. W.; Cho, H.; Bae, Y.; Kolesar, J. M.; Kwon, G. S. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs Mol. Pharmaceutics 2011, 8, 1257-1265
24. Shin, H. C.; Alani, A. W.; Rao, D. A.; Rockich, N. C.; Kwon, G. S. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs J. Controlled Release 2009, 140, 294-300
25. Hasenstein, J. R.; Shin, H.-C.; Kasmerchak, K.; Buehler, D.; Kwon, G. S.; Kozak, K. R. Antitumor activity of triolimus: a novel multidrug-loaded micelle containing paclitaxel, rapamycin, and 17-AAG Mol. Cancer Ther. 2012, 11, 2233-2242
26. Bae, Y.; Alani, A. W.; Rockich, N. C.; Lai, T. S.; Kwon, G. S. Mixed pH-sensitive polymeric micelles for combination drug delivery Pharm. Res. 2010, 27, 2421-2432
27. Shafer, A.; Zhou, C.; Gehrig, P. A.; Boggess, J. F.; Bae-Jump, V. L. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis Int. J. Cancer 2010, 126, 1144-1154
28. Treeck, O.; Wackwitz, B.; Haus, U.; Ortmann, O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells Gynecol. Oncol. 2006, 102, 292-299
29. Bae-Jump, V. L.; Zhou, C.; Boggess, J. F.; Gehrig, P. A. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells Cancer 2009, 115, 3887-3896
30. Maciag, T.; Kadish, J.; Wilkins, L.; Stemerman, M. B.; Weinstein, R. Organizational behavior of human umbilical vein endothelial cells J. Cell Biol. 1982, 94, 511-520
31. Vailhe, B.; Vittet, D.; Feige, J.-J. In vitro models of vasculogenesis and angiogenesis Lab. Invest. 2001, 81, 439-452
32. Kim, S. C.; Kim, D. W.; Shim, Y. H.; Bang, J. S.; Oh, H. S.; Kim, S. W.; Seo, M. H. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy J. Controlled Release 2001, 72, 191-202
33. Chou, T.-C.; Martin, N. CompuSyn, 1.0; ComboSyn, Inc.: Paramus, NJ, 2007.
34. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 1984, 22, 27-55
35. Schneider, C. A.; Rasband, W. S.; Eliceiri, K. W. NIH image to ImageJ: 25 years of image analysis Nat. Methods 2012, 9, 671-675
36. Al-Husein, B.; Abdalla, M.; Trepte, M.; Deremer, D. L.; Somanath, P. R. Antiangiogenic therapy for cancer: an update Pharmacotherapy 2012, 32, 1095-1111
37. Bocci, G.; Loupakis, F. The possible role of chemotherapy in antiangiogenic drug resistance Med. Hypotheses 2012, 78, 646-648
38. Huh, K. M.; Lee, S. C.; Cho, Y. W.; Lee, J.; Jeong, J. H.; Park, K. Hydrotropic polymer micelle system for delivery of paclitaxel J. Controlled Release 2005, 101, 59-68
39. Kwon, Y. S.; Hong, H. S.; Kim, J. C.; Shin, J. S.; Son, Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo Invest. Ophthalmol. Vis. Sci. 2005, 46, 454-460
40. Grant, D. S.; Williams, T. L.; Zahaczewsky, M.; Dicker, A. P. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere) Int. J. Cancer 2003, 104, 121-129
41. Shafer, A.; Zhou, C.; Gehrig, P. A.; Boggess, J. F.; Bae-Jump, V. L. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis Int. J. Cancer 2010, 126, 1144-1154
42. Parry, T. J.; Brosius, R.; Thyagarajan, R.; Carter, D.; Argentieri, D.; Falotico, R.; Siekierka, J. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries Eur. J. Pharmacol. 2005, 524, 19-29
43. Grant, D. S.; Williams, T. L.; Zahaczewsky, M.; Dicker, A. P. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere) Int. J. Cancer 2003, 104, 121-129
44. Hotchkiss, K. A.; Ashton, A. W.; Mahmood, R.; Russell, R. G.; Sparano, J. A.; Schwartz, E. L. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center Mol. Cancer Ther. 2002, 1, 1191-1200